XELOCCORD capecitabine 500 mg film-coated tablet blister pack

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

capecitabine, Quantity: 500 mg

Available from:

Accord Healthcare Pty Ltd

Pharmaceutical form:

Tablet, film coated

Composition:

Excipient Ingredients: lactose; purified talc; titanium dioxide; magnesium stearate; microcrystalline cellulose; hypromellose; croscarmellose sodium; iron oxide red; purified water; iron oxide yellow

Administration route:

Oral

Units in package:

30 Tablets in blister pack, 60 Tablets in blister pack, 120 Tablets in blister pack

Prescription type:

(S4) Prescription Only Medicine

Therapeutic indications:

Colon Cancer:,Capecitabine is indicated for the adjuvant treatment of patients with Duke?s stage C and highrisk stage B, colon cancer, either as monotherapy or in combination with oxaliplatin.,Colorectal Cancer:,Capecitabine is indicated for the treatment of patients with advanced or metastatic colorectal cancer.,Oesophagogastric Cancer:,Capecitabine is indicated for the first-line treatment of patients with advanced oesophagogastric cancer in combination with a platinum-based regimen.,Breast Cancer:,Capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated.,Capecitabine in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

Product summary:

Visual Identification: Peach coloured, oblong shaped, biconvex, film-coated tablets, debossed with 500 on one side and plain on other side.; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius

Authorization status:

Licence status A

Authorization date:

2014-07-22